Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent

British Journal of Pharmacology

Volumn 157, Issue 8, 2009, Pages 1541-1548

  Ray, G L ^a   Baidoo, K E ^a   Wong, K J ^a   Williams, M ^a   Garmestani, K ^a   Brechbiel, M W ^a   Milenic, D E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

111In; EGFR; Panitumumab; Preclinical evaluation; Radioimmunodiagnosis; Radioimmunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; PANITUMUMAB; PENTETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIODIAGNOSIS; RADIOIMMUNOTHERAPY; SERODIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; ISOTHIOCYANATES; MICE; MICE, NUDE; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 70350348660     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00327.x     Document Type: Article

References (34)

1. Baselga J (2002). Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7 (Suppl. 4): 2-8.
2. Baselga J, Arteaga CL (2005). Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459.
3. Boswell CA, Eck PK, Regino CA, Bernardo M, Wong KJ, Milenic DE et al. (2008). Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm 5: 527-539.
4. Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G et al. (1988). Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J Nucl Med 29: 1022-1030.
5. Cohenuram M, Saif MW (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18: 7-15.
6. Colcher D, Minelli MF, Roselli M, Muraro R, Simpson-Milenic D, Schlom J (1988). Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48: 4597-4603.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004). Cetuximab monotherapy and cetuximab plus irinote-can in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
8. Fraker PJ, Speck JC Jr (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80: 849-857.
9. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW (2002). A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 29: 599-606.
10. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R (2007). FDA drug approval summary: panitumumab (Vectibix). Oncologist 12: 577-583.
11. Greiner JW (1986). Recombinant human leukocyte interferon induces alterations in the antigen phenotype of human breast carcinoma cells. Anticancer Res 6: 653-658.
12. Guadagni F, Witt PL, Robbins PF, Schlom J, Greiner JW (1990). Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma. Cancer Res 50: 6248-6255.
13. Horan Hand P, Colcher D, Salomon D, Ridge J, Noguchi P, Schlom J (1985). Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 45: 833-840.
14. Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV (1999). CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol Immunol 36: 1079-1091.
15. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al. (2007). Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
16. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M et al. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2: 457-470.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275.
18. Mendelsohn J, Baselga J (2006). Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385. (Pubitemid 44142736)
19. Messersmith WA, Hidalgo M (2007). Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res 13: 4664-4666.
20. Milenic DE, Yokota T, Filpula DR, Finkelman MA, Dodd SW, Wood JF et al. (1991). Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51: 6363-6371.
21. Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D et al. (2002). In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29: 431-442.
22. Milenic DE, Brady ED, Brechbiel MW (2004a). Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3: 488-499.
23. Milenic DE, Garmestani K, Dadachova E, Chappell LL, Albert P, Hill D et al. (2004b). Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother Radiopharm 19: 135-148.
24. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A et al. (2005). Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20: 557-568.
25. Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M et al. (2008). Cetuximab: pre-clinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioim-muntherapeutic applications. Cancer Biother Radiopharm 23: 619-631.
26. Pippin CG, Parker TA, McMurry TJ, Brechbiel MW (1992). Spectropho-tometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 3: 342-345.
27. Regino CAS, Wong KJ, Milenic DE, Holmes EH, Garmestani K, Choyke PL et al. (2009). Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiop-harm 2: 9-17.
28. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
29. Siler K, Eggensperger D, Hand PH, Milenic DE, Miller LS, Houchens DP et al. (1993). Therapeutic efficacy of a high-affinity anticarcinoem-bryonic antigen monoclonal antibody (COL-1). Biotechnol Ther 4: 163-181.
30. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA et al. (2000). Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18: 1316-1323.
31. Wells A (1999). EGF receptor. Int J Biochem Cell Biol 31: 637-643.
32. Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA et al. (1997). Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans- CyDTPA. Bioorg Med Chem 5: 1925-1934.
33. Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL et al. (2007). Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 50: 4759-4765.
34. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236-1243.